Evidence map›Paper›PMID 42096086›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Renal cell carcinoma with a novel RAB1A::ALK fusion: expanding the molecular spectrum of ALK-rearranged RCC.

Claudia Andrea Gómez González, Banu Sarsik Kumbaraci, Fuat Kizilay, Serdar Kalemci, Sercan On, Sait Sen

Erratum issuedAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Claudia Andrea Gómez GonzálezDepartment of Pathology, Faculty of Medicine, Ege University, Bornova, Izmir, 35100, Türkiye. clau.gomezg@gmail.com.ORCID http://orcid.org/0000-0002-5516-2117
Banu Sarsik KumbaraciDepartment of Pathology, Faculty of Medicine, Ege University, Bornova, Izmir, 35100, Türkiye.ORCID http://orcid.org/0000-0003-4775-3942
Fuat KizilayDepartment of Urology, Faculty of Medicine, Ege University, Izmir, Türkiye.ORCID http://orcid.org/0000-0003-1856-0404
Serdar KalemciDepartment of Urology, Faculty of Medicine, Ege University, Izmir, Türkiye.ORCID http://orcid.org/0000-0002-9629-5258
Sercan OnDepartment of Medical Oncology, Faculty of Medicine, Ege University, Izmir, Türkiye.ORCID http://orcid.org/0000-0003-1461-7485
Sait SenDepartment of Pathology, Faculty of Medicine, Ege University, Bornova, Izmir, 35100, Türkiye.ORCID http://orcid.org/0000-0002-1100-6657

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma associated with anaplastic lymphoma kinase rearrangement (ALK-RCC) is a rare subtype within the category of molecularly defined renal cell carcinomas. Due to its low incidence and highly heterogeneous clinicopathological features, ALK-RCC poses a significant diagnostic challenge. The implementation of advanced molecular techniques has facilitated the identification of various fusion partners, which may influence clinical behavior and guide targeted therapies. We report a case of ALK-RCC harboring a novel fusion partner, RAB1A::ALK. This report describes the clinicopathological and molecular features of the tumor, with a particular focus on the characterization of the RAB1A gene and its documented impact on carcinogenesis and prognosis across several solid malignancies. Our findings expand the molecular spectrum of ALK-RCC and emphasize the role of comprehensive molecular profiling in uropathology.

Indexed as

Anaplastic Lymphoma KinaseBiomarkers, TumorCarcinoma, Renal CellGene RearrangementKidney NeoplasmsOncogene Proteins, Fusionrab1 GTP-Binding ProteinsHumansImmunohistochemistryMaleALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorOncogene Proteins, FusionRAB1A protein, humanrab1 GTP-Binding ProteinsALKImmunohistochemistryNGSRAB1ARCCRearrangement

Identifiers

PMID42096086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.